VLT-015 in Patients With Schizophrenia

Inclusion Criteria: * Male patients aged 18 to 50 * Availability of a voluntarily signed Information Consent (Patient Information Sheet) for participation in this clinical research and further hospitalization; * The diagnosis of schizophrenia established in the anamnesis * The patient's stay in remission\*\* based on the decision of the investigator before and after the withdrawal of maintenance therapy. Criteria determining the state of remission: * the sum of points of the Positive and Negative Symptom Scale (PANSS) according to positive Marder factor is less than 22 points, * each item score of the positive Marder factor (delusions, hallucinatory behavior, grandiosity, suspicion, stereotyped thinking, somatic anxiety, unusual thought content, decreased criticism) less than 4 points * Absence of taking antipsychotic drugs for 5 periods half-life of the drug taken; * The patient's ability to adequately cooperate (the ability to understand provided information about the clinical trial, readiness for compliance with the requirements of the study protocol); * Agree to use barrier methods of contraception during the study and within 2 months after completion of the study. Exclusion Criteria: 1. The presence of contraindications to the use of VLT-015: * dysfunction of the bone marrow; * hypersensitivity to VLT-015 and other components of the drug; * toxic or idiosyncratic granulocytopenia/agranulocytosis in history; * epilepsy; * alcohol, drug intoxication and coma; * collapse, depression of the central nervous system of any etiology; * severe kidney or heart disease; * paralytic intestinal obstruction; * glucose-galactose malabsorption; * renal or hepatic insufficiency; 2. Patients requiring medication or other concomitant therapies listed in the unacceptable concomitant therapy section; 3. The presence of prostatic hyperplasia or glaucoma in patients; 4. Diseases of the bone marrow in history; 5. Active tuberculosis, cystic fibrosis, systemic connective tissue diseases, oncological processes of any localization; 6. Severe, decompensated or unstable somatic diseases (any diseases or conditions that threaten the patient's life or worsen the prognosis patient, and also make it impossible to conduct a clinical trial); 7. Alcoholism and drug addiction at the present time, or in history; 8. Lack of patient willingness to cooperate, non-compliance of the patient; 9. Participation of the patient in any other clinical study in the last 30 days; 10. Patients planning to stay in the hospital during the study period for reasons other than the purposes of this clinical trial.